Tricida (NASDAQ:TCDA) Issues Quarterly Earnings Results

Tricida (NASDAQ:TCDA) released its earnings results on Thursday. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.12, Fidelity Earnings reports.

Shares of TCDA traded up $0.59 during trading hours on Friday, reaching $33.02. The stock had a trading volume of 295,623 shares, compared to its average volume of 186,804. Tricida has a 12 month low of $19.43 and a 12 month high of $42.80. The company has a market cap of $1.54 billion, a PE ratio of -7.12 and a beta of 0.90. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.30 and a quick ratio of 8.30. The stock has a 50-day moving average price of $34.08.

Several equities research analysts have weighed in on TCDA shares. Needham & Company LLC started coverage on Tricida in a research note on Friday, May 24th. They set a “buy” rating and a $50.00 target price for the company. Goldman Sachs Group started coverage on Tricida in a research note on Wednesday, June 26th. They set a “buy” rating and a $48.00 target price for the company. Zacks Investment Research cut Tricida from a “hold” rating to a “sell” rating in a research note on Friday, July 12th. Finally, Cowen restated a “buy” rating and set a $50.00 target price on shares of Tricida in a research note on Thursday.

In other news, insider Claire Lockey sold 40,401 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $37.10, for a total value of $1,498,877.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Dawn Parsell Otto sold 5,000 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $31.19, for a total value of $155,950.00. The disclosure for this sale can be found here. Insiders sold a total of 90,126 shares of company stock valued at $3,218,846 over the last quarter. 66.70% of the stock is owned by corporate insiders.

About Tricida

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

Featured Article: What is a Futures Contract?

Earnings History for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.